300194 Fuan Pharmaceutical
- 4.97
- +0.04+0.81%
Fuan Pharmaceutical News
Fuan Pharmaceutical (300194): Overlooked generic drug enterprise integrating API formulations
Fuan Pharmaceutical (300194) Third Quarterly Report Review: Performance Meets Expectations, Transformation and Development of Multiple Categories of Products
Fuan Pharmaceutical (300194) Quarterly Review: Mergers and Acquisitions Drive Rapid Performance Growth
Fu'an Pharmaceutical Co., Ltd. (300194): actively carry out epitaxial M & A strategy
Comment on Fu'an Pharmaceutical (300194) Annual report: the traditional business is booming and showing leads to high performance growth.
[Huajin Securities] Fu'an Pharmaceutical Co., Ltd.: the performance inflection point has passed, and the stock price is good.
Fu'an Pharmaceutical (300194): the performance inflection point has been too high to turn to a good share price.
Comments on the quarterly report of Fu'an Pharmaceutical Industry (300194): endogenous rapid growth and outstanding contribution
[southwest Securities] Fu'an Pharmaceutical Industry: endogenous rapid growth, and outstanding contribution
Fu'an Pharmaceutical (300194): the main business bottomed out and rebounded and showed the effectiveness of integration.
[southwest Securities] Fu'an Pharmaceutical: traditional main business bottomed out and rebounded, epitaxial mergers and acquisitions exceeded expectations
福安药业(300194)：传统主营触底反弹 外延并购超预期
福安药业(300194)年报及一季报点评：产品结构优化 并表提振业绩
福安药业(300194)：前途光明 道路曲折
【国联证券】福安药业业绩预告点评:前途光明,道路曲折
福安药业(300194)：外延收购贡献显著 收购只楚药业促增长
【西南证券】福安药业:外延收购贡献显著,收购只楚药业促增长
福安药业(300194)：收购只楚强化公司抗生素主业
福安药业(300194)：外延再下一城 业绩大幅提升
【华泰证券】福安药业:收购只楚,强化公司抗生素主业
Analysis
Price Target
No Data
No Data